FDA Regulation of Compounding Pharmacies: Unsolved Mysteries

by BakerHostetler

The U.S. Food and Drug Administration (FDA) has been busy since the passage of the Drug Quality and Security Act (DQSA) in November 2013. In just five short months, the FDA has issued six warning letters referencing the DQSA’s outsourcing facility provisions, published three draft guidance documents outlining its authority and enforcement priorities under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FFDCA) and conducted an “Inter-Governmental Working Meeting on Pharmacy Compounding” with officials from state boards of pharmacy and national trade organizations to discuss implementation of the DQSA. The FDA also welcomed the addition of almost 40 newly registered “outsourcing facilities” that have voluntarily registered with the FDA in exchange for the opportunity to compound drugs without a prescription for office use and to ship compounded drugs across state lines without restriction. But this flurry of activity also has resulted in several important unanswered questions under the DQSA, particularly as to where certain entities fit in relation to Section 503A, which governs traditional compounding pursuant to identifiable patient prescriptions, and Section 503B, which governs the newly created outsourcing facilities.

Limitations on Interstate Shipment of Compounded Drugs

One significant area of uncertainty involves the interplay between Section 503A and 503B and a key provision of Section 503A of the FFDCA that limits the amount of compounded prescriptions a traditional compounding pharmacy is permitted to ship across state lines. Specifically, unless the pharmacy is located in a state that has entered into a memorandum of understanding (MOU) with the FDA, Section 503A of the FFDCA prohibits the traditional compounding pharmacy from dispensing or distributing more than five percent of the pharmacy’s total prescription orders to patients outside of the state in which the pharmacy is located. This is often referred to as the “5% Rule.” More specifically, Section 503A states that drugs compounded by a traditional compounding pharmacy only qualify for exemptions from adequate directions for use, new drug application (NDA) requirements/approval and current good manufacturing practice (cGMP) requirements if, among other things, one of the following conditions is met:

  • The drugs are compounded in a state that has entered into a MOU with the FDA that addresses the distribution of “inordinate amounts” of compounded drug products interstate and provides for appropriate investigation by a state agency of complaints relating to compounded drug products distributed outside such state, or
  • If the drugs are compounded in a state that has not entered into a MOU, the drugs are compounded in quantities that do not exceed five percent of the total prescription drug orders dispensed or distributed by the pharmacy or physician.

Section 503A, which was enacted in 1997 as part of the Food and Drug Administration Modernization Act, also requires the FDA to consult with the National Associate of Boards of Pharmacy (NABP) to develop a standard MOU for use by the states in lieu of fifty separate MOUs.

Prior FDA Regulatory Efforts and Constitutional Uncertainty

In January 1999, the FDA, in consultation with the NABP, published a draft standard MOU in the Federal Register and requested comment regarding its provisions. The FDA received over 6,000 comments on the draft MOU. Under the draft MOU, the amount of compounded drug shipped interstate was considered “inordinate” if either of the following conditions were met:

  • The number of compounded prescriptions distributed interstate was equal to or greater than 20 percent of the total number of compounded prescriptions dispensed or distributed (both intrastate and interstate) annually, or
  • The number of compounded prescriptions distributed interstate was less than 20 percent of the total number of prescriptions dispensed, but the total amount of one or more individual compounded drug constituted more than 5 percent of the total number of prescriptions dispensed or distributed.

Distribution to patients interstate but within 50 miles of the compounding pharmacy was excluded from the calculation described above, as was compounding in response to an emergency. Additionally, under the draft MOU, the states were responsible for investigating complaints stemming from the interstate shipment of compounded drugs, including reports of serious adverse events, compounding that failed to qualify for Section 503A exemptions or compounding of adulterated or misbranded drugs.

But shortly after publication of the draft MOU, the constitutionality of Section 503A was called into question. Specifically, under Section 503A, only drugs compounded pursuant to an “unsolicited” prescription were eligible for exemptions from adequate directions for use, NDA and GMP requirements. In 1999, a group of pharmacists successfully challenged the constitutionality of this advertising restriction in Western States Medical Center v. Shalala, a decision that was affirmed by the 9th Circuit, which went on to hold that the unconstitutional provision was not severable from the remainder of Section 503A. Shortly thereafter, the 5th Circuit reached the opposite conclusion in Medical Center Pharmacy v. Mukasey, holding that only the advertising restrictions in Section 503A were invalid and that the remaining provisions were severable from the statute. As a result of the uncertainty created by this circuit split, the FDA did not enforce certain provisions of Section 503A, including the 5% Rule, and the draft MOU was never finalized.

The DQSA Brings Both Clarity and Chaos

The DQSA settled the unconstitutional aspects of Section 503A by striking the term “unsolicited” from the statute and removing the prohibition on advertising. Now, the FDA has indicated that it intends to enforce the 5% Rule, but questions remain as to how and when. In its recently published draft guidance, “Pharmacy Compounding of Human Drug Products Under Section 503A of the [FFDCA],” the FDA attempted to answer some of these questions by stating that it intends to publish a new draft MOU for comment that will replace the 1999 draft and indicating that it does not intend to enforce the 5% Rule until 90 days after the MOU has been finalized. Additionally, the 5% Rule and the MOU were key topics addressed during the Inter-Governmental Working Meeting on Pharmacy Compounding, so much so that Dr. Jane Axelrad, Associate Director for Policy at the FDA’s Center for Drug Evaluation and Research and a key player in compounding pharmacy regulation, prepared a presentation specifically addressing the topic. Her presentation focused on issues that had been left unsettled in 1999, such as how the FDA should define “inordinate amounts” in the MOU and whether the restrictions on interstate distribution should account for contiguous states.

But other questions still remain, particularly for compounding pharmacies that rely on interstate distribution of drugs compounded pursuant to patient prescriptions. Limiting these entities’ distribution of compounded drug product to 5 percent or even 20 percent could be devastating to their business models. Additionally, while registering as an outsourcing facility would allow the entities to distribute compounded drug products interstate without limitation, doing so would require that the entities comply with the cGMP standards, such as batch sterility testing and other manufacturing-oriented standards that may be difficult if not impossible for entities compounding drugs pursuant to specific patient prescriptions to meet. How will the FDA account for these entities? Will they be expected to register as outsourcing facilities? If so, will the FDA create cGMP exemptions for these entities? It will be interesting to see how the FDA balances patient needs (e.g., rare custom mix medication or patients in states that may not have enough compounding pharmacies) with the 5% Rule.

The answers to these and many other questions are coming soon, as the FDA prepares to roll out additional guidance regarding implementation of the DQSA.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:


BakerHostetler on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.